Raymond James & Associates Soligenix, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 04, 2020
SELL
$1.7 - $2.61 $33,507 - $51,443
-19,710 Closed
0 $0
Q3 2019

Nov 07, 2019
BUY
$0.72 - $1.31 $3,600 - $6,550
5,000 Added 33.99%
19,710 $19,000
Q2 2017

Aug 14, 2017
BUY
N/A
14,710
14,710 $30,000

Others Institutions Holding SNGX

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About SOLIGENIX, INC.

SNGX Quotes by TradingView
  • Ticker SNGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,105,200
  • Market Cap $124M
  • Description
  • Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has c...
More about SNGX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email